Trial
NCT00470535
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Roswell Park Cancer Institute
Collaborators
—
Condition
Pancreatic Cancer
Intervention
erlotinib hydrochloride
Why stopped
This study was terminated earlier due to a phase III study that showed this drug inferior to sorafenib
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-23